International Ophthalmology

, Volume 27, Issue 2–3, pp 143–148 | Cite as

Vogt–Koyanagi–Harada disease in Hispanic patients

  • Somsiri Sukavatcharin
  • Julie H. Tsai
  • Narsing A. Rao
Original Paper



To describe the clinical features of Vogt–Koyanagi–Harada disease (VKH) in Hispanic patients.


Retrospective review of the records of 48 Hispanic patients diagnosed with VKH. The patients were divided into two groups: patients in the early phase of VKH (n = 11) were those who presented within 1 month after the onset of symptoms; patients in the late or chronic VKH phase (n = 37) were those who presented 6 months after onset of symptoms. Demographic data, clinical features, complications and initial and final visual acuity for each patient were recorded.


All 11 patients in early phase VKH presented with bilateral uveitis (100%). Meningismus was noted in six cases and auditory disturbances in three. Ocular findings for these 11 patients included exudative retinal detachment in ten patients (91%) and marked optic disc edema in one patient. In the late phase VKH, ocular findings included sunset glow fundus in 26 patients (70%), peripheral nummular scars in 27 (73%), and retinal pigment epithelium hyperplasia in seven (19%). Extraocular manifestations noted in this group of patients included vitiligo in four, poliosis in six, and alopecia in five; auditory disturbances were found in four patients. The visual acuity improved in 60–70% of the patients after treatment with corticosteroids alone or in combination with immunosuppressive agents.


Hispanic patients with VKH often present without extraocular changes during early phase of the disease. However, once the disease evolves into the chronic phase, integumentary system involvement may become apparent in some patients.


Corticosteroid Early phase VKH Hispanic Late phase VKH Vogt–Koyanagi–Harada disease 


  1. 1.
    Moorthy RS, Inomata H, Rao NA (1995) Vogt–Koyanagi–Harada syndrome. Surv Ophthalmol 39:265–292PubMedCrossRefGoogle Scholar
  2. 2.
    Sugiura S (1978) Vogt–Koyanagi–Harada disease. Jpn J Ophthalmol 22:9–35Google Scholar
  3. 3.
    Alaez C, del Pilar Mora M, Arellanes L, Cano S, Perez-Luque E, Vazquez MN, et al. 1999 Strong association of HLA class II sequences in Mexicans with Vogt–Koyanagi–Harada’s disease. Hum Immunol 60:875–882PubMedCrossRefGoogle Scholar
  4. 4.
    Levinson RD, See RF, Rajalingam R, Reed EF, Park MS, Rao NA, et al. (2004) HLA-DRB1 and -DQB1 alleles in mestizo patients with Vogt–Koyanagi–Harada’s disease in Southern California. Hum Immunol 65:1477–1482PubMedCrossRefGoogle Scholar
  5. 5.
    Shimizu K (1973) Harada’s, Behcet’s, Vogt–Koyanagi syndromes−are they clinical entities? Trans Am Acad Ophthalmol Otolarnyngol 77:OP281–OP290Google Scholar
  6. 6.
    Ohno S, Char DH, Kimura SJ, O’Connor GR (1977) Vogt–Koyanagi–Harada syndrome. Am J Ophthalmol 83:735–740PubMedGoogle Scholar
  7. 7.
    Snyder DA, Tessler HH (1980) Vogt–Koyanagi–Harada syndrome. Am J Ophthalmol 90:69–75PubMedGoogle Scholar
  8. 8.
    Nussenblatt RB (1988) Clinical studies of Vogt–Koyanagi–Harada’s disease at the National Eye Institute, NIH, USA. Jpn J Ophthalmol 32:330–333PubMedGoogle Scholar
  9. 9.
    Beniz J, Forster DJ, Lean JS, Smith RE, Rao NA (1991) Variations in clinical features of the Vogt–Koyanagi–Harada syndrome. Retina 11:275–280PubMedCrossRefGoogle Scholar
  10. 10.
    Rosen E (1945) Uveitis, with poliosis, vitiligo, alopecia and dysacusia (Vogt–Koyanagi syndrome). Arch Ophthalmol 33:281–292Google Scholar
  11. 11.
    Minakawa R, Ohno S, Hirose S, Kotake S, Miyajima T, Tagawa Y, et al. (1985) Clinical manifestation of Vogt–Koyanagi–Harada’s disease. Jpn J Clin Ophthalmol 39:1249–1253Google Scholar
  12. 12.
    Ohno S, Minakawa R, Matsuda H (1988) Clinical studies of Vogt–Koyanagi–Harada’s disease. Jpn J Ophthalmol 32:334–343PubMedGoogle Scholar
  13. 13.
    Read RW, Holland GN, Rao NA, Tabbara KF, Ohno S, Arellanes-Garcia L, et al. (2001) Revised diagnostic criteria for Vogt–Koyanagi–Harada disease: report of an international committee on nomenclature. Am J Ophthalmol 131:647–652PubMedCrossRefGoogle Scholar
  14. 14.
    Bouchenaki N, Herbort CP (2001) The contribution of indocyanine green angiography to the appraisal and management of Vogt–Koyanagi–Harada disease. Ophthalmology 108:54–64PubMedCrossRefGoogle Scholar
  15. 15.
    Rutzen AR, Ortega-Larrocea G, Frambach DA, Rao NA (1995) Macular edema in chronic Vogt–Koyanagi–Harada syndrome. Retina 15:475–479PubMedGoogle Scholar
  16. 16.
    Wallyn RH, Hilton GF (1979) Subretinal fibrosis in retinal detachment. Arch Ophthalmol 97:2128–2129PubMedGoogle Scholar
  17. 17.
    Moorthy RS, Rajeev B, Smith RE, Rao NA (1994) Incidence and management of cataracts in Vogt–Koyanagi–Harada syndrome. Am J Ophthalmol 118:197–204PubMedGoogle Scholar
  18. 18.
    Forster DJ, Rao NA, Hill RA, Nguyen QH, Baerveldt G (1993) Incidence and management of glaucoma in Vogt–Koyanagi–Harada syndrome. Ophthalmology 100:613–618PubMedGoogle Scholar
  19. 19.
    Hayasaka S, Okabe H, Takahashi J (1982) Systemic corticosteroid treatment in Vogt–Koyanagi–Harada disease. Graefes Arch Clin Exp Ophthalmol 218:9–13PubMedCrossRefGoogle Scholar
  20. 20.
    Sasamoto Y, Ohno S, Matsuda H (1990) Studies on corticosteroid therapy in Vogt–Koyanagi–Harada disease. Ophthalmologica 201:162–167PubMedCrossRefGoogle Scholar
  21. 21.
    Read RW, Rechodouni A, Butani N, Johnston R, LaBree LD, Smith RE, et al. (2001) Complications and prognostic factors in Vogt–Koyanagi–Harada disease. Am J Ophthalmol 131:599–606PubMedCrossRefGoogle Scholar
  22. 22.
    Rubsamen RE, Gass JDM (1991) Vogt–Koyanagi–Harada syndrome. Clinical course, therapy, and long-term visual outcome. Arch Ophthalmol 109:682–687PubMedGoogle Scholar
  23. 23.
    Keino H, Goto H, Usui M (2002) Sunset glow fundus in Vogt–Koyanagi–Harada disease with or without chronic ocular inflammation. Graefes Arch Clin Exp Ophthalmol 240:878–882PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2007

Authors and Affiliations

  • Somsiri Sukavatcharin
    • 1
    • 2
  • Julie H. Tsai
    • 1
    • 2
  • Narsing A. Rao
    • 1
    • 2
  1. 1.Doheny Eye InstituteLos AngelesUSA
  2. 2.Department of OphthalmologyKeck School of Medicine, University of Southern CaliforniaLos AngelesUSA

Personalised recommendations